Drilldown: Medicines
Medicines > classes 
:
Classic Psychedelic or
Sedative-Hypnotic or
[[:Category:ACE_inhibitors|ACE inhibitor]]
:
Classic Psychedelic or
Sedative-Hypnotic or
[[:Category:ACE_inhibitors|ACE inhibitor]] Use the filters below to narrow your results.
generic:
brand:
None (78) ·
(none, never marketed) (1) ·
Altace (1) ·
Dalmane (1) ·
Delysid (historical, Sandoz, withdrawn 1965) (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lotensin (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
THIP (1) ·
Vasotec, Vasotec IV, Epaned (1) ·
Versed (1) ·
Xyrem (1) ·
Zestril, Prinivil, Qbrelis (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) ·
GABAA positive allosteric modulator (15) ·
Potent 5-HT2A agonist (5) ·
None (4) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
Contains LSA (2) ·
Contains mescaline (2) ·
GABAA potentiator and direct activator (2) ·
Melatonin receptor agonist (2)
uses:
None (99) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"' (1) ·
'"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"' (1) ·
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) ·
'"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"' (1)
starting dose:
None (99) ·
10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) ·
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d (1) ·
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) ·
5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
None (99) ·
1.25, 2.5, 5, 10 mg capsules (1) ·
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) ·
2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) ·
5, 10, 20, 40 mg tablets (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration:
halflife:
None (98) ·
10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' (1) ·
3–5 hours (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) ·
~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"' (1) ·
~13-17 hours (ramiprilat, the active metabolite)'"`UNIQ--ref-00000C32-QINU`"' (1)
bioavailability:
None (98) ·
70–90% (oral) (1) ·
Not formally characterized in humans. (1) ·
~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) ·
~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' (1) ·
~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1) ·
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1)
pregnancy:
None (98) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-0000005B-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000A24-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension'"`UNIQ--ref-00000C34-QINU`"' (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Not established (1)
Showing below up to 104 results in range #1 to #104.